1. Home
  2. TLSA vs VATE Comparison

TLSA vs VATE Comparison

Compare TLSA & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.95

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$7.46

Market Cap

103.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLSA
VATE
Founded
2013
1994
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
103.5M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
TLSA
VATE
Price
$0.95
$7.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 553.2K
84.3K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,246,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 12.55
52 Week Low
$0.76
$3.75
52 Week High
$2.33
$21.30

Technical Indicators

Market Signals
Indicator
TLSA
VATE
Relative Strength Index (RSI) 49.82 45.26
Support Level $0.90 $6.48
Resistance Level $1.20 $8.23
Average True Range (ATR) 0.09 0.51
MACD 0.01 0.06
Stochastic Oscillator 62.70 49.59

Price Performance

Historical Comparison
TLSA
VATE

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

Share on Social Networks: